ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2856

Update on Long-Term Outcomes after Reversible Cerebral Vasoconstriction Syndrome (RCVS)

Seby John1, Aneesh Singhal2, Leonard H. Calabrese3, Ken Uchino4, Tariq Hammad3, Stewart Tepper3, Mark Stillman3 and Rula A Hajj-Ali5, 19500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, 2Neurology, Massachusetts General Hospital, Boston, MA, 3Cleveland Clinic Foundation, Cleveland, OH, 4Neurology, Cleveland Clinic Foundation, Cleveland, OH, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cerebrovascular disease, outcomes and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose
RCVS is characterized by acute onset of severe headaches, with or without neurologic deficit with evidence of reversible cerebral vasoconstriction. We have previously reported data on long-term outcome on 20 patients with RCVS. Herein, we are validating our previous report by including data from two large academic centers.   

Objectives:
i) To assess stroke and headache outcomes using validated measures ii) To determine the impact of RCVS on health related quality of life (QoL). 

Methods
The following validated questionnaires were mailed to patients recruited from RCVS registries of Cleveland Clinic and Massachusetts General Hospital: Headache screening form, Headache Impact Test (HIT-6), Migraine Disability Assessment Test (MIDAS), Barthel Index (BI), EuroQoL (EQ-5D-5L) and Patient Health Questionnaire (PHQ-9).

Results
Of the 191 patients in the RCVS registries, 109 could be contacted and 45 responded to the questionnaires.  This included 41 (91%) females, with a median follow-up time after symptom onset of 78 months (range 4-254 months). Forty six % had prior migraine, 31% developed ischemic stroke, 18% intracerebral hemorrhage, and 44% had convexal subarachnoid hemorrhage. After RCVS resolution, 24 (53%) patients continued to have headache, but the majority (88%) reported improvement in its severity. Five (14%) patients reported severe impact on activities of daily living from headaches as measured by the HIT-6 and MIDAS scales. The majority (97.5%) of patients were functionally independent based on their BI scores. EQ-5D-5L measurements showed that patients did better in the domains of mobility, self-care and usual activities, as compared to pain and anxiety/depression. Patients with persistent headache had significantly higher levels of pain as measured by EQ-5D-5L. Depression assessment using the PHQ-9 revealed only 1 (3%) patient reporting severe depression. There was a trend towards greater patients with persistent headache having more severe degrees of depression. There was no difference among all the outcome measures between the two centers.  

Conclusion
More than half of patients with RCVS will continue to have headache long-term. They are not similar to the RCVS onset headache and are markedly improved from the initial headache. Although close to two-thirds of patients suffered from an initial ischemic or hemorrhagic stroke, almost all were independent with little functional disability.  However, pain and anxiety/depression might be associated with lower QoL Headache may be a potential factor aggravating pain and anxiety/depression in those patients with persistent headache. This larger data from two different centers validate our previous report.


Disclosure:

S. John,
None;

A. Singhal,
None;

L. H. Calabrese,
None;

K. Uchino,
None;

T. Hammad,
None;

S. Tepper,

Please see notes,

9;

M. Stillman,
None;

R. A. Hajj-Ali,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/update-on-long-term-outcomes-after-reversible-cerebral-vasoconstriction-syndrome-rcvs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology